Saturday, May 11, 2024 3:46:06 PM
I ran your post through an AI bs detector, and it was identified as bs.
“The statement by Nemesis18 about the NICE appraisal of DCVAX-L is not only speculative and unfounded but also a clear example of disinformation designed to manipulate perceptions unfairly. Here are the key issues:
1. **Unfounded Assertions:** The claim that NICE's Health Economist will outright reject DCVAX-L is irresponsible and misleading. NICE decisions are based on a rigorous evaluation of all available evidence, including clinical and economic data, not on conjecture or preemptive judgments.
2. **Misrepresentation of Process:** Suggesting a "stated 87% failure rate" misrepresents how NICE assesses treatments. NICE uses detailed health economic analysis and clinical effectiveness data in their evaluations. Decisions are made after thorough consideration, not based on arbitrary or misrepresented statistics.
3. **Inaccurate Role Description:** The role of NICE and its health economists is grossly oversimplified in the statement. Their goal is to ensure treatments are both effective and cost-effective, without being influenced by external financial concerns of the biotech companies.
4. **Speculative and Misleading Tone:** The tone and content aim to provoke unwarranted fear and uncertainty about DCVAX-L's review process, which is typical of "short and distort" tactics where misinformation is spread to manipulate stock prices.
**Advisory:
**Beware of 'Short and Distort' Tactics:** Be cautious of speculative and unfounded statements designed to manipulate perceptions. These tactics are often used in attempts to influence stock prices by spreading negative rumors.
**Rely on Trustworthy Sources:** For accurate and reliable information about DCVAX-L and its regulatory status, consult peer-reviewed medical journals, official NICE documentation, and other authoritative sources like regulatory announcements.
By relying on credible, peer-reviewed sources and official statements, you can avoid being misled by reckless and harmful disinformation that seeks to distort the truth for speculative gain.
For the most accurate and reliable information, refer to the official NICE website (https://www.nice.org.uk/guidance/indevelopment/gid-ta10143) and trusted medical publications accessible through databases like https://pubmed.ncbi.nlm.nih.gov/ ”
https://www.nature.com/articles/s41467-024-48073-y
https://www.jci.org/articles/view/169314
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM